“Characterization of ORKA-001, a Novel Extended Half-life Monoclonal Antibody Targeting IL-23 for the Treatment of Psoriasis”, J of Skin, vol. 9, no. 2, p. s527, Mar. 2025, doi: 10.25251/skin.10.supp.527.